Jazz Pharmaceuticals (JAZZ) reported Q4 non-GAAP earnings late Tuesday of $6.60 per diluted share, up from $5.02 a year earlier.
Analysts polled by Capital IQ expected $5.81.
Revenue for the quarter ended Dec. 31 was $1.09 billion, up from $1.01 billion a year earlier.
Analysts surveyed by Capital IQ expected $1.06 billion.
For the full year 2025, the company expects diluted EPS of $22.50 to $24.00 on revenue of $4.15 billion to $4.40 billion. Analysts are looking for $22.03 and $4.32 billion, respectively.
Shares of Jazz Pharmaceuticals were down 2.6% in recent after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。